Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
Subscribe To Our Newsletter & Stay Updated
